Home > News > Starpharma’s VivaGel™ Advance to Third Stage
August 2nd, 2004
Starpharma’s VivaGel™ Advance to Third Stage
Abstract:
Starpharma Holdings Limited announced today that VivaGel™, its investigational new drug for the prevention of HIV, is advancing to the next stage of dosing in the current Phase 1 study. VivaGel™ is the first drug product in the world based upon nanoscale structures called dendrimers, to enter human trials.
Source:
Starpharma
Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||